A basic understanding of congenital extrahepatic portosystemic shunt: incidence, mechanism, complications, diagnosis, and treatment

Haowen Tang1, Peipei Song2, Zhiqiang Wang3, Bing Han4, Xiangfei Meng1, Yingwei Pan1, Xuan Meng1,*, Weidong Duan1,*

1Department of Hepatobiliary Surgery, First Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China; 2The Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan; 3Department of Hepatobiliary Surgery, Qinghai Red Cross Hospital, Xining, China; 4Department of General Surgery, Shanxian Central Hospital, Heze, China.

SUMMARY
Extrahepatic portosystemic shunt belongs to a family of rare vascular abnormalities. The clinical importance and manifestations of this vascular abnormality range from asymptomatic cases to liver or metabolic dysfunctions of various degrees. Congenital extrahepatic portosystemic shunt, also termed as Abernethy malformation, is a very rare congenital vascular malformation in which splenomesenteric blood drains into a systemic vein, bypassing the liver through a complete or partial extrahepatic shunt. So far, limited cases of congenital extrahepatic portosystemic shunt have been reported. In this review, incidence, mechanisms, complications, diagnoses and treatments of congenital extrahepatic portosystemic shunt are described.

Keywords
Congenital extrahepatic portosystemic shunt, incidence, mechanism, complications, diagnosis, treatment, review

1. Introduction
Extrahepatic portosystemic shunt belongs to a family of rare vascular abnormalities. Clinical importance of this vascular abnormality lies in its broad spectrum of symptoms and complications, ranging from incidentally discovered asymptomatic cases to liver or metabolic dysfunctions of various degrees and even severe clinical scenarios, which are caused by variations in sites or types of shunt (1). Congenital extrahepatic portosystemic shunt (CEPS), also termed as Abernethy malformation, is a very rare congenital vascular malformation in which splenomesenteric blood drains directly into a systemic vein, bypassing the liver through a complete or partial extrahepatic shunt. Since it was first documented in 1793 by John Abernethy (2), the number of reported cases has progressively increased (3). As is proposed by Morgan and Superina, CEPS is classified into two variants based on absence (type 1) or presence (type 2) of intrahepatic portal supply (4,5). Type 1 is described as complete portosystemic shunts (Figure A, end-to-side, a complete extrahepatic shunt) and the liver is not perfused with portal blood; whereas type 2 is defined as a certain proportion of portal blood perfused to the liver and the remaining portal flow bypasses the liver and is diverted into a systemic vein through a partial shunt (Figure B, side-to-side, a partial extrahepatic shunt) (4,6). This classification has been widely recognized and referred by a lot of studies because of its practical understanding of pathophysiologic implications and managements of included cases. In this review, we mainly present incidence, mechanisms, complications, diagnoses and treatments of CEPS.

2. Incidence
Knowledge about CEPS is scarce given that the low incidence of this malformation has prevented realization of large studies. Several issues stay unanswered, such as the actual incidence of CEPS. With limited sources, incidence of CEPS was once described close to 1/30,000 births and the prevalence proportion of permanent CEPS was 1/50,000, which came from results of a nationwide galactosemia survey. Because CEPS gave rise to increased levels of bile acids and galactoses, the incidence was extrapolated. Of note, only 7 CEPS cases were diagnosed and biases might remain in that survey (7,8). To a certain degree, the assumption that
CEPS could be diagnosed through increases in blood galactoses after birth yet requires further validations, and this incidence ought to be accepted with suspicions of a certain degree (7). No remarkable gender predominance was found in CEPS (9); however, it has been described in certain researches that type 1 shunts feature a significant female predilection of 61-78%, while no clear explanation is given (7,10). Thus, future studies to systematically evaluate presence of CEPS are warranted.

3. Mechanism

Rather limited researches have explored etiology mechanisms of CEPS. Two possible explanations have dominated literatures on development of CEPS: i) A genetic origin and complex congenital malformation processes: such malformations are considered to originate from an insult occurring in week 4-10 of embryological development, which is a crucial stage for hepatic and systemic vessel formations. And this to certain degree give evidence to the fair association with cardiac and other vascular anomalies (7); ii) The absence of ductus venosus during fetal stage: abnormal vessels may develop in association with occlusions or agenesis of ductus venosus. Through abnormal vessels, oxygenated blood from the umbilical vein flows into the fetal heart. Afterwards, certain vessels may persist and develop into an abnormal shunt, resulting in hypoplasia of the portal venous system (11,12). As is shown in literatures, absence of ductus venosus has been documented among some CEPS children (13,14).

Etiology mechanisms of CEPS differ significantly from that of acquired extrahepatic portosystemic shunts. As to acquired extrahepatic portosystemic shunts, due to liver cirrhosis, collateral vessels would generate or reopen to compensate for blocked or narrowed portal veins, so as to lower pressures on the portal tree. Gradually, this will result in an acquired extrahepatic portosystemic shunt (15,16). Hence, variations of therapeutic strategies should be noted for CEPS and acquired extrahepatic portosystemic shunts.

4. Complications

Spectrums of clinical variants of CEPS ranges from completely asymptomatic forms to severe forms of hepatic encephalopathy, hepatopulmonary syndromes (HPS) and pulmonary arterial hypertension (PaHT).

4.1. Hepatic encephalopathy

Hepatic encephalopathy is a common clinical manifestation in symptomatic patients, with a reported incidence of as high as 17-30% (7,14,17,18). Blood ammonia produced by gastrointestinal tracts directly bypasses the liver and flows into inferior vena cava, then it is metabolized in astrocytes to glutamine, which in turn has deleterious effects on the brain. This phenomenon is more frequently seen among older patients. Most children with CEPS are asymptomatic, which proves that children are more resistant to hepatic encephalopathies than adults. Partially, this might be caused by ageing of brain, decreased blood-brain barriers and losses of brain reserves, all of which make patients more vulnerable to harmful metabolic products such as ammonia and facilitate the revelations of hepatic encephalopathies (19-21). In a previous international observational study, Baiges, A. described that 29% of patients with CEPS presented hepatic encephalopathies at a certain time during the study. Median age at hepatic encephalopathy onset or diagnosis was 12 years (range, 5-65). Different patterns of hepatic encephalopathy were documented with a fair predominance of chronic hepatic encephalopathy: 73.7% featured persistent hepatic encephalopathy with permanent cognitive impairment, 11.0% featured recurrent hepatic encephalopathy, and 15.3% featured episodic hepatic encephalopathy. In most cases, in accordance with West-Haven standard, episodes of hepatic encephalopathies were of moderate intensities (20).

4.2. Pulmonary complications

Patients with CEPS will be frequently associated with severe pulmonary complications, such as HPS (7,22) and PaHT (14,23). Developments of HPS and PaHT can be linked with vasoactive mediators from intestines (22,24,25). Such mediators skip hepatic circulations and directly approach the pulmonary vascular bed, causing pulmonary circulation imbalances and inducing a long-term pulmonary vasoconstriction in PaHT (9,24) or, reversely, a pulmonary vasodilation in HPS (26).

HPS is a clinical relationship between hepatic diseases and existence of pulmonary vascular dilatations, which is characterized by presence of dyspnea and hypoxia and can result in arterial oxygenation abnormalities of a certain range. Prevalence of HPS...
among patients with CEPS is still not clear, because mild HPS are often asymptomatic and a comprehensive study on lungs cannot always be carried out on all patients. Hence, an actual prevalence cannot be accurately predicted. In addition, it is recognized that CEPS should be considered as one of the etiologies of HPS (27). Since the first case report about CEPS with HPS by Papagiannis (28), there have been more than 20 similar cases described in literatures (22,29,30). A baseline comprehensive assessment on pulmonary complications is suggested to be undergone. In follow-up durations, transcutaneous oxygen saturation measurements can be of help in early and primary detections of HPS.

It has been demonstrated that PaHT is a considerable issue among CEPS patients, inducing symptomatic dyspnea in about 80% of cases; it has been shown by data that PaHT occurred in 13-66% of children with CEPS (17,23). When carefully screened, PaHT is also manifested on nearly 11% of asymptomatic patients (20). Rarity of such disease and the small amount of patient series have led to a rather broad percentage range. Despite virous hypotheses and reports, PaHT mechanisms stay controversial. From histological perspective, the lungs present microthrombotic lesions, and it is considered that PaHT resulted from recurrent microemboli originating in the mesenteric circulation and travelling through a portosystemic shunt directly to the lungs (23). Symptoms of PaHT vary from disturbed consciousness to syncope. Right ventricular hypertrophies, decompressions of left ventricle or an increased estimated right ventricular systolic pressure are vital signs of an echocardiography. Notably, PaHT is not seemingly related to severity or degree of a shunt, while it features a decreased outcome, with a reported mortality of nearly 50% (7). As PaHT can occur in a broad range of age, periodic and regular surveillances for PaHT may be of a great significance during follow-ups.

4.3. Liver nodules

An abnormal shunt of blood leads to non-specific liver disturbances because of uneven portal flow perfusions and arterialisations (compensatory increases in hepatic arterial flows). In ischemic liver parenchyma, absent or reduced portal flows result in lacks of nutrition and fatty degenerations in hepatocytes; thusly, liver dysfunctions occur, certain normal hepatocytes diminish, and hepatic atrophy follows; in well perfused areas, regenerative nodule generated. Altogether, these elements contribute to abnormal hepatic developments and functions, which will bring an incentive to nodule generations (21,31,32).

Nodular liver tumors are commonly seen in as many as 40-65% of patients with CEPS. Although most of such tumors are benign, among other neoplastic lesions, malignancies such as hepatocellular carcinomas and adenomas have also been reported (20,21,33,34). In a case series involving 26 CEPS patients with liver nodules, 70% of them had focal nodular hyperplasia or regenerative nodular hyperplasia, 20% had hepatocellular carcinoma, and 10% had adenomas; also, it has been shown in researches that 21% of patients had single nodules and 79% had multiple nodules (9,14,20,21,31). Hence, it should be noted that performances of a rigorous and periodic screening of liver nodules for patients with CEPS is of significant needs and values. Furthermore, researchers have also advocated that it is sensible to term cirrhosis strategies of hepatocellular carcinoma surveillence every half year (20).

5. Diagnosis

CEPS can be diagnosed at any age, which is often in childhood during the setting of neonatal cholestasis, hypergalactosemia, failures to thrive, psychomotor delays or other congenital defects. Prenatal diagnoses will be considered through ultrasound detections of abnormal communication vessels between portal and peripheral venous systems or an enlarged umbilical vein (9,14,35,36). In adulthood, CEPS could be incidentally diagnosed through abdominal ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) in the screening of unexplained abdominal pains, abnormal liver functions and hepatic nodules, or etc. (37-39). Of note, for accurate diagnoses of CEPS, one should first excluded potential acquired portosystemic shunts, such as those patients with hepatic cirrhosis, with or without concomitant presentations of portal hypertension (40), and surgically created portosystemic shunts (41). Generally, non-congenital or acquired shunts are small, tortuous peripheral vessels, and CEPS patients will not present hepatic cirrhosis or portal hypertension imaging features (ascites, varices, or splenomegaly) (42,43).

Ultrasound is widely utilized in abdominal diseases for its safe and fast imaging properties. Primarily, it can be a useful diagnostic tool to identify presence of portosystemic shunts. Doppler ultrasound is of special diagnostic values for its abilities to assess vessel flow directions. As is reported previously (35), clinically asymptomatic shunts have been occasionally diagnosed in children through ultrasound during galactosaemia test. Ponziani FR, et al. have summarized concomitant presence of five ultrasound signs to strengthen the suspicion of CEPS (39), including: i) Solid focal lesions in liver parenchyma; ii) Portal trunk absence/hypoplasia; iii) Deficiencies of intrahepatic portal vessels and flow signals; iv) Existence of porto/systemic shunts; v) Hepatic artery hypertrophies. However, ultrasound might fail to accurately detect inapparent or small shunts. Hence, anomalies identified by ultrasound should be further confirmed through other imaging methods (44).

Radiological methods like CT or MRI are preferred investigations to confirm a portosystemic shunt. Asymptomatic CEPS are often diagnosed through incidental presentations on CT or MRI scans in
abdominal imaging. CT and MRI are also of great values in further classifications of shunts and measurements of accompanying anomalies (10). Postprocessing technologies, such as multiplanar reformations, have supplied additional information about diagnoses and managements.

A Contrast-enhanced CT can document anatomies, locations and sizes of abnormal shunts. With techniques like maximum intensity projection and multiplanar reconstruction, much information will be provided by CT, including shunt courses, sizes and orientations, which help both radiologists and surgeons to make or choose suitable treatment regimens.

Furthermore, MR can be used to visualize shunts and avoid radiation exposures for both radiologists and patients. Particularly, in assessments of associated liver nodules, MRI includes diffusion sequences and shows unique advantages over CT (10). Compared to CT, MRI would be preferred as the first-choice test. A research team from Canada analyzed 61 reported cases of CEPS and recommended MRI as a superior tool in diagnoses and classifications of CEPS as well as examinations of associated cardiovascular and hepatic abnormalities (42). Furthermore, MRI angiography serves as a reliable and noninvasive examination for hepatic vascular anatomies. Despite this, CT can be reserved for patients who are noncooperative or have specific contraindications. Traditionally, conventional angiography is regarded as a gold standard for detections of portomesenteric vasculatures. However, improvements in CT and MRI techniques have changed the situation. Currently, conventional angiography is not necessarily a must in CEPS diagnoses, for CT and MRI can provide accurate diagnoses in most cases.

According to existing findings on nuclear medicine researches, iodine-123 iodoamphetamine could also be used to measure shunt dynamics (10,19). Furthermore, serum ammonia level is useful, although it is a non-specific and investigative adjunct. In 66-100% of CEPS cases, a heightened level of serum ammonia is found (7). Hence, concentrations of ammonia without known hepatic cirrhosis or portal hypertension ought to imply subsequent examinations for CEPS (45). In certain cases, liver biopsies may illustrate small portal venules within portal triads, which is indicative of type 2 shunt (42).

6. Treatment

Currently, there is no standard therapeutic approach to treat extrahepatic portosystemic shunts due to rarity of such diseases (46). Several approaches including shunt closures through surgical or radiological interventions and liver transplantations have been proposed, but clear comparisons among different treatment strategies are still unavailable. Treatment strategies are decided according to shunt types, locations, symptoms severities and related complications. There still remains debate regarding therapeutic strategies for asymptomatic cases (1,46). Conservative managements including lifestyle changes, such as protein restrictions as well as lactulose and non-absorbable antibiotics administrations, may be recommended in asymptomatic shunts. Yet, presence of shunts could potentially develop clinical implications, such as supplying a route for intestinal toxic materials to bypass hepatic circulations, immune surveillances as well as offering a possible route for lung tumor metastases of gastrointestinal tumors (1,19). A Japanese research team has previously observed natural courses of 51 patients with CEPS and found that spontaneous shunt closures were never evident. Hence, early detections and suitable therapies are vital for a good prognosis (32).

6.1. Shunt closure for type 2 CEPS

Discrepancies regarding management of patients with asymptomatic type 2 did exist. Researchers from University of Catania chose active surveillances (46). However, more experts urge early and active interventions to be mandatory (9,47). When a clear diagnosis of extrahepatic shunt is made, it is important to remark that shunt closures facilitating progressive redirections of portal blood flowing to livers are possible and essential for such patients. As is proved in treatments of Abernethy malformations, shunt closures are especially useful in improving hepatic encephalopathies. Baiges A, et al. suggested that shunt closures had a huge efficacy in managing most shunt complications and, most interestingly, preventing their occurrences (3); this is in agreement with findings of Papamichail M. et al., who proved that early occlusions would reverse associated complications (48). Sanada Y., et al. and Pathak A., et al. had also demonstrated that patients with CEPS and hepatic encephalopathies can benefit by early shunt occlusion surgeries (49,50).

Therefore, shunt closures must always be considered for symptomatic patients and should also be regarded as a prophylactic treatment early in evolutions of the disease to prevent developments of severe complications. Earlier studies have shown that for shunt occlusions, either interventional embolization or surgical ligations (open or laparoscopic surgical techniques) can be choices of treatment that lead to rapid ameliorations of symptoms and normalizations of ammonia levels (25,51). Likewise, multiple results have proved that the associated HPS could also be resolved by shunt closures (25,26,52,53). The choice from an interventional embolization or a surgical ligation depends upon medical expertise, shunt vessel anatomies and sizes as well as individual general conditions (48,54,55). For patients with wide and short shunt vessels or those who fail to receive embolization, a surgical ligation will be preferred (54,56).
Shunt closures are not a feasible option for patients with type 1 CEPS, as the shunt stands for the only drainage path of mesenteric and splenic venous blood. Thusly, liver transplantation serves as effective therapeutic approaches for both liver and pulmonary complications. Literature has described the successful application of liver transplantation for CEPS patients with severe complications (including refractory encephalopathy, CEPS associated with biliary atresia, or patients with severe HPS) (37,57,58).

Timing of liver transplantations for type 1 CEPS is still a matter of debate. Results from Japan show that prophylactic liver transplantations should be justified prior to occurrences of severe pulmonary complications (HPS or PaHT), because such complications would complicate or even preclude liver transplantations (37). However, Guerin F, et al. found that asymptomatic patients with type 1 CEPS ought not to receive liver transplantations as a prophylactic option, which would make them experience prolonged periods of immunosuppression (7). Sakamoto S, et al. reviewed a collection of 34 transplantation cases of CEPS and concluded that presence of pulmonary complications was an early indication of liver transplantations; in the review, 30 out of 34 CEPS cases with liver transplantations stayed alive after a median follow-up period of one and a half years, indicating an encouraging outcome (6). Sanada Y, et al. also revealed that liver transplantations could be potentially curative for patients with symptomatic type 1 CEPS (49). In most reported cases, liver transplantations provide a complete resolution for associated complications. Technical difficulties of portal system anatomies and reconstructions are main challenges (39).

6.3. Management of liver nodules

When liver nodules are identified in patients with CEPS, differential diagnoses of malignant and benign tumors will be crucial for determination of following treatments. For benign tumors, conservative treatments and regular follow-ups should be suggested. In cases of malignant tumors, subsequent surgical interventions like biopsies will be adequate.

At last, a close surveillance is indicated for patients with such vascular malformations. Long-term follow-ups will create a good clinical compliance and provide a comprehensive understanding and management of disease processes.

7. Conclusion

Differential diagnoses between CEPS and acquired portosystemic shunts are of much importance. When a clear diagnosis of CEPS is made, it is important to remark that active interventions are possible and essential for such patients. As to type 1 CEPS, liver transplantation serves as an effective therapeutic approach for both liver and pulmonary complications; as with type 2 CEPS, shunt closures must always be considered for symptomatic patients and should also be regarded as a prophylactic treatment early in evolutions of the disease, so as to prevent developments of severe complications. Yet, knowledge about CEPS is scarce due to its low incidence. Future studies on systematical explorations on CEPS are warranted.

Acknowledgements

This study was supported by Beijing Natural Science Foundation (NO.7204309) and Beijing New Star of Science and Technology Foundation (NO.2017B503).

References

1. Matthews TJ, Trochsiel MI, Bridgewater FH, Maddern GJ. Systematic review of congenital and acquired portal-systemic shunts in otherwise normal livers. Br J Surg. 2014; 101:1509-1517.

2. Abernethy J. Account of two instances of uncommon formation in the viscera of the human body: from the philosophical transactions of the royal society of London. Med Facts Obs. 1797; 7:100-108.

3. Baiges A, Turon F, Simon-Taler M, et al. Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. Hepatology. 2019.

4. Mathai SV, Kondray V, Salloum E, Kukreja K, Tavri S. Role of interventional radiology in the diagnosis and management of congenital extrahepatic portosystemic shunts: Two case reports. Indian J Radiol Imaging. 2019; 29:219-222.

5. Morgan G, Superina R. Congenital absence of the portal vein: two cases and a proposed classification system for portosystemic vascular anomalies. J Pediatr Surg. 1994; 29:1239-1241.

6. Sakamoto S, Shigeta T, Fukuda A, Tanaka H, Nakazawa A, Nosaka S, Uemoto S, Kasahara M. The role of liver transplantation for congenital extrahepatic portosystemic shunt. Transplantation. 2012; 93:1282-1287.

7. Guerin F, Blanc T, Gauthier F, Abella SF, Branchereau S. Congenital portosystemic vascular malformations. Semin Pediatr Surg. 2012; 21:233-244.

8. Sakura N, Mizoguchi N, Eguchi T, Ono H, Mawatari H, Naitou K, Ito K. Elevated plasma bile acids in hypergalactosaemic neonates: a diagnostic clue to portosystemic shunts. Eur J Pediatr. 1997; 156:716-718.

9. Sokollik C, Bandsma RH, Gana JC, van den Heuvel M, Ling SC. Congenital portosystemic shunt: characterization of a multisystem disease. J Pediatr Gastroenterol Nutr. 2013; 56:675-681.

10. Alonso-Gamarras E, Parron M, Perez A, Prieto C, Hierro L, Lopez-Santamaria M. Clinical and radiologic manifestations of congenital extrahepatic portosystemic shunts: a comprehensive review. Radiographics. 2011; 31:707-722.

11. Acherman RJ, Evans WN, Galindo A, Collazos JC, Rothman A, Mayman GA, Luna CF, Rollins R, Kip KT, Berthody DP, Restrepo H. Diagnosis of
absent ductus venosus in a population referred for fetal echocardiography: association with a persistent portosystemic shunt requiring postnatal device occlusion. J Ultrasound Med. 2007; 26:1077-1082.

12. Shen O, Valsky DV, Messing B, Cohen SM, Lipschuetz M, Yagel S. Shunt diameter in agenesis of the ductus venosus with extrahepatic portosystemic shunt impacts on prognosis. Ultrasound Obstet Gynecol. 2011; 37:184-190.

13. Manning N, Impey L, Lindsell D, Lakhou K. Prenatally diagnosed portocalval shunt and postnatal outcome: a case report. Prenat Diagn. 2004; 24:537-540.

14. Franchi-Abella S, Branchereau S, Lambert V, Fabre M, Steinberg C, Losay J, Riou J-Y, Pariente D, Gauthier F, Jacquemin E, Bernard O. Complications of Congenital Portosystemic Shunts in Children: Therapeutic Options and Outcomes. Journal of Pediatric Gastroenterology and Nutrition. 2010.

15. Wu Q, Shen L, Chu J, Ma X, Jin B, Meng F, Chen J, Wang Y, Wu L, Han J, Zhang W, Ma W, Wang H, Li H. Characterization of uncommon portosystemic collateral circulations in patients with hepatic cirrhosis. Oncol Lett. 2015; 9:347-350.

16. Zardi EM, Uwechje V, Caccavo D, Pellegrino NM, Caccapiaglia F, Di Matteo F, Dobrina A, Laghi V, Afeltra A. Portosystemic shunts in a large cohort of patients with liver cirrhosis: detection rate and clinical relevance. J Gastroenterol. 2009; 44:76-83.

17. Kim MJ, Ko JS, Seo JK, Yang HR, Chang JY, Kim GB, Cheon JE, Kim WS. Clinical features of congenital portosystemic shunt in children. Eur J Pediatr. 2012; 171:395-400.

18. Lautz TB, Tantemasyap N, Rowell E, Superina RA. Management and classification of type II congenital portosystemic shunts. J Pediatr Surg. 2011; 46:308-314.

19. Diyar R, Wells T, Haboubi H. Congenital extrahepatic portosystemic shunt. Br J Hosp Med (Lond). 2015; 76:424-425.

20. Baiges A, Turon F, Simon-Talero M, et al. Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. Hepatology. 2020; 71:658-669.

21. Sorkin T, Strautnieks S, Foskett P, Peddu P, Thompson RJ, Heaton N, Morotti R. Congenital Extrahepatic Portosystemic Shunt (Abernethy Malformation Type Ib) With Associated Hepatocellular Carcinoma: Case Report and Literature Review. Pediatr Dev Pathol. 2017; 20:354-362.

22. Sharma R, Suddle A, Quaglia A, Peddu P, Karani J, Saiyudas T, Heaton N. Congenital extrahepatic portosystemic shunt complicated by the development of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015; 14:552-557.

23. Uchino T, Matsuda I, Endo F. The long-term prognosis of congenital portosystemic venous shunt. J Pediatr. 1999; 135:254-256.

24. Benedict M, Rodriguez-Davalos M, Emre S, Walther Z, Morotti R. Congenital Extrahepatic Portosystemic Shunt (Abernethy Malformation Type Ib) With Associated Hepatocellular Carcinoma: Case Report and Literature Review. Pediatr Dev Pathol. 2017; 20:354-362.

25. Song P, Cai Y, Tang H, Li C, Huang J. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. Biosci Trends. 2017; 11:389-398.

26. Venkat-Raman N, Murphy KW, Ghaus K, Teoh TG, Higham JM, Carvalho JS. Congenital absence of portal vein in the fetus: a case report. Ultrasound Obstet Gynecol. 2001; 17:71-75.

27. Athanasiadis A, Karavida A, Chondromatidou S, Tsitouridis J, Tarlatzis B. Prenatal diagnosis of Abernethy malformation by three-dimensional ultrasonography. Ultrasound Obstet Gynecol. 2015; 46:638-639.

28. Kobayashi N, Niwa T, Kirikoshi H, Fujita K, Yoneda M, Saito S, Nakajima A. Clinical classification of congenital extrahepatic portosystemic shunts. Hepatol Res. 2010; 40:585-593.

29. Barchetti F, Pellegrino L, Al-Ansari N, De Marco V, Sarpato P, Ialongo P. Congenital absence of the portal vein in a middle-aged man. Surg Radiol Anat. 2011; 33:369-372.

30. Ponziani FR, Faccia M, Zocco MA, Giannelli V, Pellicelli A, Ettorre GM, De Mattaehns N, Pizzolante F, De Gaetano AM, Riccardi L, Pompili M, Rapaccini GL. Congenital extrahepatic portosystemic shunt: description of four cases and review of the literature. J Ultrasound. 2019; 22:349-358.

31. Konstas AA, Digumarthy SR, Avery LL, Wallace KL, Lisovsky M, Misraji J, Hahn PF. Congenital portosystemic shunts: imaging findings and clinical presentations in 11 patients. Eur J Radiol. 2011; 80:175-181.

32. Hu GH, Shen LG, Yang J, Mei JH, Zhu YF. Insight into hepatopulmonary syndrome. Pediatr Pulmonol. 2002; 34:391-394.

33. Alvarez AE, Ribeiro AnF, Hessel G, Baracat J, Ribeiro JD. Abernethy malformation: One of the etiologies of hepatopulmonary syndrome. Pediatric Pulmonology. 2002; 34:391-394.

34. Papagiannis J, Kanter RJ, Effman EL, Pratt PC, Marcille R, Browning IB, 3rd, Armstrong BE. Polysplenia with pulmonary arteriovenous malformations. Pediatr Cardiol. 1993; 14:127-129.

35. Ohnishi Y, Ueda M, Doi H, Kasahara M, Haga H, Kamei H, Ogawa K, Ogura Y, Yoshitoshi EY, Tanaka K. Successful liver transplantation for congenital absence of the portal vein complicated by intrapulmonary shunt and brain abscess. Journal of Pediatric Surgery. 2005; 40:e1-e3.

36. Bernard O, Franchi-Abella S, Branchereau S, Pariente D, Gauthier F, Jacquemin E. Congenital portosystemic shunts in children: recognition, evaluation, and management. Semin Liver Dis. 2012; 32:273-287.

37. Sharma R, Suddle A, Quaglia A, Peddu P, Karani J, Saiyudas T, Heaton N. Congenital extrahepatic portosystemic shunt complicated by the development of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015; 14:552-557.

38. Uehara M, Oda M, Doi H, Kasahara M, Haga H, Kamei H, Ogawa K, Ogura Y, Yoshitoshi EY, Tanaka K. Successful liver transplantation for congenital absence of the portal vein complicated by intrapulmonary shunt and brain abscess. Journal of Pediatric Surgery. 2005; 40:e1-e3.

39. Konstas AA, Digumarthy SR, Avery LL, Wallace KL, Lisovsky M, Misraji J, Hahn PF. Congenital portosystemic shunts: imaging findings and clinical presentations in 11 patients. Eur J Radiol. 2011; 80:175-181.
congenital absence of the portal vein: is it rare? World J Gastroenterol. 2008; 14:5969-5979.

42. Murray CP, Yoo SJ, Babyn PS. Congenital extrahepatic portosystemic shunts. Pediatr Radiol. 2003; 33:614-620.

43. Lisovsky M, Konstas AA, Misdraji J. Congenital extrahepatic portosystemic shunts (Abernethy malformation): a histopathologic evaluation. Am J Surg Pathol. 2011; 35:1381-1390.

44. Altavilla G, Cusatelli P. Ultrastructural analysis of the liver with portal vein agenesis: a case report. Ultrastruct Pathol. 1998; 22:477-483.

45. Lux D, Naito A, Harikrishnan S. Congenital extrahepatic portosystemic shunt with progressive myelopathy and encephalopathy. Pract Neurol. 2019; 19:368-371.

46. Timpanaro T, Passanisi S, Sauna A, Trombatore C, Pennisi M, Petrillo G, Smilari P, Greco F. Congenital portosystemic shunt: our experience. Case Rep Pediatr. 2015; 2015:691618.

47. Shah A, Aziz A, Awwad A, Ramjas G, Higashi Y. Incidental radiological diagnosis of asymptomatic Abernethy malformations-two case reports. BJR Case Rep. 2017; 3:20150496.

48. Papamichail M, Ali A, Quaglia A, Karani J, Heaton N. Liver resection for the treatment of a congenital intrahepatic portosystemic venous shunt. Hepatobiliary Pancreat Dis Int. 2016; 15:329-333.

49. Sanada Y, Urihashi T, Ihara Y, et al. The role of operative intervention in management of congenital extrahepatic portosystemic shunt. Surgery. 2001; 130:763-770.

50. Pathak A, Agarwal N, Mandiya J, Gehlot P, Dhaneria M. Abernethy malformation: a case report. BMC Pediatr. 2012; 12:57.

51. Kimura T, Soh H, Hasegawa T, Sasaki T, Kuroda S, Yuri E, Tomoda K, Fukuzawa M. Laparoscopic correction of congenital portosystemic shunt in children. Surg Laparosc Endosc Percutan Tech. 2004; 14:285-288.

52. Emre S, Arnon R, Cohen E, Morotti RA, Vaysman D, Shneider BL. Resolution of hepatopulmonary syndrome after auxiliary partial orthotopic liver transplantation in Abernethy malformation. A case report. Liver Transpl. 2007; 13:1662-1668.

53. Kuo MD, Miller FJ, Lavine JE, Peterson M, Finch M. Exploiting phenotypic plasticity for the treatment of hepatopulmonary shunting in Abernethy malformation. J Vasc Interv Radiol. 2010; 21:917-922.

54. Papamichail M, Pizanias M, Heaton N. Congenital portosystemic venous shunt. Eur J Pediatr. 2018; 177:285-294.

55. Kanazawa H, Nosaka S, Miyazaki O, Sakamoto S, Fukuda A, Shigeta T, Nakazawa A, Kasahara M. The classification based on intrahepatic portal system for congenital portosystemic shunts. J Pediatr Surg. 2015; 50:688-695.

56. Kainz A, Onitake Y, Kamei N, Tajima G, Sakura N, Sueda T, Hiqama E. Surgical intervention for patent ductus venosus. Pediatr Surg Int. 2010; 26:1025-1030.

57. Shinkai M, Ohhama Y, Nishi T, Yamamoto H, Fujita S, Take H, Adachi M, Tachibana K, Aida N, Kato K, Tanaka Y, Takemka S. Congenital absence of the portal vein and role of liver transplantation in children. J Pediatr Surg. 2001; 36:1026-1031.

58. Ohnishi Y, Ueda M, Doi H, Kasahara M, Haga H, Kamei H, Ogawa K, Ogura Y, Yoshitoshi EY, Tanaka K. Successful liver transplantation for congenital absence of the portal vein complicated by intrapulmonary shunt and brain abscess. J Pediatr Surg. 2005; 40:e1-3.

Received February 25, 2020; Revised March 26, 2020; Accepted April 10, 2020

*Address correspondence to:
Weidong Duan and Xuan Meng, Department of Hepatobiliary Surgery, First Medical Center of Chinese PLA General Hospital, Chinese PLA Medical School, 28 Fuxing Road, Haidian, Beijing 100853, China.
E-mail: duanwd301@163.com (Duan WD), dreamingfrog@163.com (Meng X)

Released online in J-STAGE as advance publication April 13, 2020.